Updated meta-analysis on the risk of melanoma associated with phosphodiesterase type 5 inhibitors. Kreuz M, Moraes FCA, Lobo AOM, Skov RPH, et al. Melanoma Res 2025 Jun 6. doi: 10.1097/CMR.0000000000001049.

Read + Share

Amedeo Smart

Independent Medical Education

Kreuz M, Moraes FCA, Lobo AOM, Skov RPH, et al. Updated meta-analysis on the risk of melanoma associated with phosphodiesterase type 5 inhibitors. Melanoma Res 2025 Jun 6. doi: 10.1097/CMR.0000000000001049.
PMID: 40478908